Prolymphocytic Leukaemia (PLL) (DBCOND0066166)

Identifiers

Synonyms

Pro-Lymphocytic Leukemia / Prolymphocytic Leukemia / Prolymphocytic leukaemia / Leukemia, Prolymphocytic / Prolymphocyctic Leukemia / Prolymphocytic leukemia of B-cell type / Pro-lymphocytic leukaemia / Prolymphocytic leukemia (morphologic abnormality) / Prolymphocytic leukemia (disorder)

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06001385	HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis	Busulfan Coenzyme M Cyclophosphamide Fludarabine Melphalan Mycophenolate mofetil Tacrolimus	treatment	2	recruiting
NCT01589302	PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia	Ibrutinib Tyrosine	treatment	2	active_not_recruiting
NCT01126502	Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia	Alvespimycin	treatment	1	terminated
NCT00898079	Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer	No drug interventions	Not Available	Not Available	completed
NCT04191187	Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies	Fludarabine Melphalan	treatment	2	active_not_recruiting
NCT04195633	Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies	Cyclophosphamide Cyclosporine Filgrastim Fludarabine Mycophenolate mofetil Mycophenolic acid Treosulfan	treatment	2	recruiting
NCT00890747	Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy	Sunitinib	treatment	1	completed
NCT05805605	Allo HSCT Using RIC and PTCy for Hematological Diseases	Allopurinol Cyclophosphamide Fludarabine Mycophenolate mofetil Sirolimus	treatment	2	recruiting
NCT01129193	AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma	AR-42	treatment	1	completed
NCT01558778	Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	Not Available	withdrawn
NCT01254578	Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers	Lenalidomide	treatment	1	completed
NCT00719888	Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease	Cyclophosphamide Cyclosporine Fludarabine Mycophenolate mofetil Thiotepa	treatment	2	active_not_recruiting
NCT01076556	Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Alvocidib Cyclophosphamide Rituximab	treatment	1	terminated
NCT01484015	Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia	Cefepime	treatment	1	completed
NCT00025415	Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction	Imatinib	treatment	1	completed
NCT00309842	Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases	Cyclophosphamide Cyclosporine Filgrastim Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT03246906	Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation	Cyclophosphamide Cyclosporine Mycophenolate mofetil Sirolimus	treatment	2	active_not_recruiting
NCT02296918	Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL	Acalabrutinib Obinutuzumab Rituximab Venetoclax	treatment	1	active_not_recruiting
NCT00060424	Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT02662296	Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant	Ibrutinib Idelalisib	treatment	2	withdrawn
NCT00104858	Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Cyclosporine Fludarabine Mycophenolate mofetil Rituximab	treatment	2	completed
NCT02661035	Allo HSCT Using RIC for Hematological Diseases	Allopurinol Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT01093586	Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Busulfan Cyclophosphamide Cyclosporine Methylprednisolone Methylprednisolone hemisuccinate Mycophenolate mofetil	treatment	2	completed
NCT00735930	Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Alvocidib Lenalidomide	treatment	1	completed
NCT03314974	Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders	No drug interventions	treatment	2	recruiting
NCT00281931	Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia	Cyclophosphamide Fludarabine Rituximab	treatment	2	terminated
NCT02556931	Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies	Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT03185494	Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22	No drug interventions	treatment	1 / 2	unknown_status
NCT01199562	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant	Foscarnet Ganciclovir Valganciclovir	Not Available	Not Available	completed
NCT01212380	Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)	Carfilzomib	treatment	1	completed
NCT01864889	Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19	No drug interventions	treatment	Not Available	unknown_status
NCT02285244	Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation	Sotrastaurin	treatment	2	withdrawn
NCT01735604	Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy	No drug interventions	treatment	1 / 2	unknown_status
NCT02722668	UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep	Cyclophosphamide Fludarabine Mycophenolate mofetil Sirolimus	treatment	2	active_not_recruiting
NCT01231412	Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant	Cyclosporine Fludarabine Mycophenolate mofetil Sirolimus	treatment	3	completed
NCT04411043	Observatory of Prolymphocytic Leukemia T	No drug interventions	Not Available	Not Available	recruiting
NCT02029443	ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia	Acalabrutinib	treatment	1 / 2	active_not_recruiting
NCT00005803	Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma	Beta-D-Glucose Carmustine Cyclophosphamide Cyclosporine Cytarabine Etoposide Fludarabine Mechlorethamine Mycophenolate mofetil	treatment	1 / 2	completed
NCT01527045	Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies	Atorvastatin Cyclosporine Fludarabine Mycophenolate mofetil	prevention	2	completed
NCT02991898	Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies	No drug interventions	treatment	2	terminated
NCT00343798	A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies	Cyclophosphamide Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1	completed
NCT01629511	Allogeneic Stem Cell Transplant for CLL	Aloe vera leaf Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Ascorbic acid Busulfan Clofarabine Filgrastim Gemcitabine Glycerin Methopterin Methotrexate Nicotinamide Tacrolimus Vitamin A	treatment	1 / 2	terminated
NCT00089011	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer	Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00112593	Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	Not Available	completed
NCT00098371	Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia	Alvocidib	treatment	2	terminated
NCT00098488	17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia	Rituximab Tanespimycin	treatment	1	terminated
NCT02530515	Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia	No drug interventions	treatment	2	completed
NCT01588015	Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	1	completed
NCT01251575	Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant	Cyclosporine Fludarabine Mycophenolate mofetil Sirolimus	treatment	2	completed
NCT03097770	Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20	No drug interventions	treatment	1 / 2	completed
NCT01962636	Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases	Cyclophosphamide Cyclosporine Fludarabine	treatment	Not Available	recruiting
NCT00278213	Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia	Alemtuzumab Cyclophosphamide Fludarabine Mitoxantrone	treatment	2	completed
NCT01231919	MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia	No drug interventions	treatment	1	completed
NCT00005786	Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia	Arsenic trioxide Arsenous acid	treatment	Not Available	terminated
NCT00387426	Sunitinib in Treating Patients With Idiopathic Myelofibrosis	Sunitinib	treatment	2	terminated
NCT01029366	CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy	Tisagenlecleucel	treatment	1	completed
NCT01515176	Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia	Dinaciclib Ofatumumab	treatment	1 / 2	completed
NCT01053494	Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer	No drug interventions	supportive_care	Not Available	completed
NCT01129180	Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma	Azacitidine Bortezomib Bortezomib D-mannitol	treatment	1	completed
NCT02005289	Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL	Lenalidomide Tafasitamab	treatment	2	active_not_recruiting
NCT02303392	Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma	Escitalopram Ibrutinib Selinexor	treatment	1	unknown_status
NCT02007044	Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia	Ibrutinib Rituximab	treatment	2	active_not_recruiting
NCT00612612	Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia	Fludarabine Obatoclax Rituximab	treatment	1	terminated
NCT01419795	Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant	Lenalidomide Rituximab	treatment	2	terminated
NCT00546793	Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL	Veltuzumab	treatment	1 / 2	completed
NCT01419691	Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)	Auranofin	treatment	2	completed
NCT01955668	AZD6738 First Time in Patient Multiple Ascending Dose Study	Ceralasertib	treatment	1	completed
NCT01217749	Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL	Ibrutinib Ofatumumab	treatment	1 / 2	completed